• Explore /
  • Poster
  • / Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC).

Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

Satoshi Yuki

Satoshi Yuki

Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan

Satoshi Yuki , Makio Gamoh , Tadamichi Denda , Atsuo Takashima , Shin Takahashi , Masato Nakamura , Hisatsugu Ohori , Tatsuro Yamaguchi , Yoshimitsu Kobayashi , Hideo Baba , Masanori Kotake , Kenji Amagai , Hitoshi Kondo , Ken Shimada , Atsushi Sato , Chikashi Ishioka , Keigo Komine , Kota Ouchi , Satoshi Morita , Yoshito Komatsu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Anal and Colorectal Cancer

Track

Colorectal Cancer,Anal Cancer

Sub Track

Translational Research

Clinical Trial Registration Number

UMIN000007834

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 169)

Abstract #

169

Poster Bd #

H11

Abstract Disclosures

Similar Posters

First Author: Scott Kopetz

First Author: Scott Kopetz

First Author: Scott Kopetz

First Author: James J. Lee